Valeant Pharmaceuticals Intl Inc (VRX) Given Sector Perform Rating at Royal Bank Of Canada

Royal Bank Of Canada reaffirmed their sector perform rating on shares of Valeant Pharmaceuticals Intl Inc (TSE:VRX) in a research note issued to investors on Monday morning, reports. Royal Bank Of Canada currently has a C$46.00 price objective on the specialty pharmaceutical company’s stock.

Several other research analysts also recently commented on VRX. TD Securities dropped their price objective on shares of Valeant Pharmaceuticals Intl from C$45.00 to C$38.00 in a report on Wednesday, June 8th. Scotiabank dropped their price objective on shares of Valeant Pharmaceuticals Intl from C$35.00 to C$32.00 and set a sector perform rating for the company in a report on Monday, July 25th. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. The stock currently has a consensus rating of Hold and an average price target of C$38.67.

Shares of Valeant Pharmaceuticals Intl (TSE:VRX) opened at 32.95 on Monday. Valeant Pharmaceuticals Intl has a 52-week low of $24.32 and a 52-week high of $240.40. The firm has a 50-day moving average price of $36.76 and a 200-day moving average price of $35.98. The stock’s market capitalization is $11.45 billion.

About Valeant Pharmaceuticals Intl

Valeant Pharmaceuticals International, Inc is a specialty pharmaceutical and medical device company. The Company is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices), which are marketed directly or indirectly in over 100 countries.

Stock Target Prices

Receive News & Ratings for Valeant Pharmaceuticals Intl Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals Intl Inc and related companies with's FREE daily email newsletter.

Leave a Reply

© 2006-2016 Mideast Time.